BioLife Solutions, Inc. (NASDAQ:BLFS) Given Consensus Rating of “Moderate Buy” by Brokerages

BioLife Solutions, Inc. (NASDAQ:BLFS) has been assigned an average recommendation of “Moderate Buy” from the five research firms that are presently covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, three have issued a buy rating and one has assigned a strong buy rating to the company. The average 12 month target price among brokers that have covered the stock in the last year is $32.00.

A number of equities research analysts have weighed in on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of BioLife Solutions in a report on Wednesday, January 21st. UBS Group reissued a “buy” rating on shares of BioLife Solutions in a report on Monday, December 29th. Wall Street Zen raised shares of BioLife Solutions from a “hold” rating to a “buy” rating in a report on Saturday, February 28th. Zacks Research raised shares of BioLife Solutions from a “hold” rating to a “strong-buy” rating in a report on Friday, January 23rd. Finally, Northland Securities set a $34.00 target price on shares of BioLife Solutions in a report on Monday, January 5th.

Insider Activity at BioLife Solutions

In other news, insider Karen A. Foster sold 96,923 shares of the company’s stock in a transaction on Thursday, March 5th. The shares were sold at an average price of $20.15, for a total value of $1,952,998.45. Following the sale, the insider directly owned 113,742 shares of the company’s stock, valued at approximately $2,291,901.30. This represents a 46.01% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Over the last 90 days, insiders have sold 99,641 shares of company stock valued at $2,009,000. Corporate insiders own 2.20% of the company’s stock.

Institutional Investors Weigh In On BioLife Solutions

Institutional investors have recently modified their holdings of the company. Global Retirement Partners LLC bought a new stake in shares of BioLife Solutions in the 4th quarter valued at $30,000. Kemnay Advisory Services Inc. bought a new stake in shares of BioLife Solutions in the 4th quarter valued at $35,000. Hantz Financial Services Inc. boosted its stake in shares of BioLife Solutions by 54.1% in the 3rd quarter. Hantz Financial Services Inc. now owns 1,877 shares of the medical equipment provider’s stock valued at $48,000 after purchasing an additional 659 shares during the last quarter. Quarry LP boosted its stake in shares of BioLife Solutions by 50.9% in the 3rd quarter. Quarry LP now owns 2,113 shares of the medical equipment provider’s stock valued at $54,000 after purchasing an additional 713 shares during the last quarter. Finally, PNC Financial Services Group Inc. boosted its stake in shares of BioLife Solutions by 82.0% in the 3rd quarter. PNC Financial Services Group Inc. now owns 4,425 shares of the medical equipment provider’s stock valued at $113,000 after purchasing an additional 1,994 shares during the last quarter. 93.24% of the stock is owned by institutional investors.

BioLife Solutions Price Performance

BLFS opened at $19.74 on Monday. BioLife Solutions has a fifty-two week low of $17.86 and a fifty-two week high of $29.62. The firm has a market capitalization of $953.44 million, a price-to-earnings ratio of -179.44 and a beta of 2.00. The company’s 50 day moving average price is $20.74 and its two-hundred day moving average price is $23.95.

About BioLife Solutions

BioLife Solutions (NASDAQ:BLFS) specializes in biopreservation and cold chain workflow solutions for cell and gene therapies, regenerative medicine and other advanced biologics. The company develops and markets proprietary cryopreservation media and technology platforms designed to maintain cell viability and functionality during processing, storage and transport. BioLife’s product portfolio addresses critical steps in the manufacturing and distribution of cell-based products, helping life science researchers and biopharmaceutical manufacturers protect and preserve living cells.

The company’s flagship offerings include CryoStor, a family of serum-free cryopreservation media; HypoThermosol, a hypothermic storage solution for short-term cell and tissue preservation; and the ThawSTAR system, an automated cell thawing instrument that delivers controlled and reproducible warming of frozen cell therapies.